Ancora Innovation

What Ancora Innovation does

Ancora Innovation, LLC is a translational research funding entity established on April 6, 2018 as a collaboration between Vanderbilt University and Deerfield Management. The company provides Vanderbilt principal investigators with capital, infrastructure, and operational support to execute novel and potentially transformative drug discovery projects targeting life-altering diseases. Deerfield committed up to $65 million in initial funding, with additional capital available for spin-off companies that emerge from successful Ancora projects. Project selection and advancement are managed through a joint operations committee comprising equal Vanderbilt and Deerfield representatives, with a dedicated Alliance Manager (Margaret Read) embedded at Vanderbilt.

Ancora's core offering is the Ancora Innovation Funding Program, structured as a translational research partnership rather than a traditional commercial product. By 2022 the collaboration had supported four drug discovery and development programs, including therapeutics for Charcot-Marie-Tooth disease (a peripheral nerve disorder) and a rare form of epilepsy. Ancora also benefits from its parent Deerfield's broader healthcare ecosystem, including the Cure Innovation Index, a systematic ranking of the top 303 U.S. biomedical institutions. Ancora has no public listing, no disclosed revenue, and operates with 1-10 employees from a Deerfield office at 345 Park Avenue South, New York.

The business model is best characterized as a curated, institution-specific venture philanthropy and translational research platform. Revenue mechanics, if any, would emerge via licensing royalties or equity in spin-off companies, but the entity currently functions as a pass-through for Deerfield capital into Vanderbilt research rather than a standalone revenue-generating business. Deerfield has replicated the Ancora model with the Broad Institute of MIT and Harvard and with Johns Hopkins University, indicating the Ancora structure is a template rather than a one-off.

Name

Ancora Innovation

Legal name

Ancora Innovation, LLC

Website

https://ancorainnovation.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Ancora Innovation is a Vanderbilt University and Deerfield Management translational research partnership that provides Vanderbilt scientists with up to $65 million in funding and operational support to advance novel drug discovery programs toward clinical therapeutics and potential spin-off companies.

Ownership category

akta.pro rank

Product category

Translational Research Funding

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Research & Science Grantmaking Foundations (BPAGAKAI)

akta.pro secondary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Translational research funding
• Drug discovery collaboration
• Academic industry partnership
• Biomedical venture funding
• Therapeutics development

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Deerfield Management Funding: Deerfield Management provides up to $65 million in initial funding to support promising Vanderbilt translational research. Additional capital is available for spin-off companies that emerge from Ancora projects showing commercial potential.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Ancora Innovation provides translational research funding and drug development support to Vanderbilt University scientists, supplying capital and infrastructure to execute novel therapeutics research projects, with up to $65 million in initial funding from Deerfield Management and additional capital available for spin-off companies emerging from successful projects. The company operates a structured joint operations committee governance model for project selection, evaluation, and advancement, and channels Deerfield's drug development expertise to advance academic research into clinical therapeutics.

Product overview

Ancora Innovation is a unified drug discovery and development funding initiative formed as a collaboration between Vanderbilt University and Deerfield Management in April 2018. The core offering is the Ancora Innovation Funding Program, which provides Vanderbilt scientists with capital and infrastructure for novel research, with up to $65 million in initial funding. The Spin-off Company Capital Investment module provides additional capital for startup companies emerging from successful Ancora projects. Through the Cure Innovation Index partnership, the ecosystem offers benchmarking services for biomedical institutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Ancora Innovation Funding Program A venture funding and drug development collaboration that empowers Vanderbilt University scientists with capital and infrastructure to execute novel and potentially transformative research projects, with up to $65 million in initial funding from Deerfield Management and selection and advancement managed through a joint operations committee.
• Spin-off Company Capital Investment Additional capital investments into successful start-up companies that spin out of Ancora Innovation projects with commercial potential, providing operational support and funding for companies emerging from the research collaboration.

Quantifiable outcome

• Four drug discovery and development programs supported through the collaboration

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Vanderbilt UniversitycoreStrategic or Co-development Partner · 6 April 2018Strategic collaboration focused on the union of Vanderbilt's innovative life science discovery efforts and Deerfield's commitment to accelerating state-of-the-art drug development. The partnership aims to translate research in Vanderbilt faculty laboratories into clinical therapeutics through project funding and operational support. The selection and development of projects is managed through a joint operations committee comprising equal Vanderbilt and Deerfield representatives.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Deerfield-Broad Institute Collaboration: Deerfield Management's parallel academic translational research partnership with the Broad Institute of MIT and Harvard, using the same model of dedicated capital, operational support, and spin-off investment rights — directly comparable structure and economics to Ancora.
• Deerfield-Johns Hopkins Collaboration: Deerfield's additional academic translational research partnership with Johns Hopkins, structured similarly to Ancora with dedicated capital and a joint steering committee — same parent, same template, comparable pipeline dynamics.
• BridgeBio Pharma: Genetic and rare disease-focused drug development company that translates academic discoveries into clinically validated therapies; shares Ancora's emphasis on rare/orphan diseases and academic-originated pipelines.
• Lexicon Pharmaceuticals: Academic-genomics-driven drug discovery and development company founded on research from academic medical centers; comparable academic-discovery-originated translational model targeting novel biology.
• Atlas Venture: Early-stage biotech venture capital firm that builds companies from academic science with operational support, mirroring the capital-plus-infrastructure approach that Deerfield provides to Ancora's Vanderbilt programs.

Broad incumbents

• Pfizer Centers for Therapeutic Innovation: Pfizer's academic-industry partnership program that funds and co-develops translational research with leading medical institutions; broader pharma-led version of the same academic-collaboration model Ancora operates.

Emerging players

• ARCH Venture Partners: Venture capital firm that creates and funds biotech companies built on academic research breakthroughs; similar academic-sourcing-driven model but with broader portfolio construction across multiple universities.
• Flagship Pioneering: Biotech creation platform that originates and builds new therapeutic companies from scientific hypotheses, often tied to academic research; comparable academic-to-company translational pathway, but at much larger scale.
• Versant Ventures: Healthcare-focused venture capital firm that builds biotech companies from academic and scientific discoveries with dedicated operational support; overlapping model of capital plus company-building infrastructure.

Others

• NIH National Center for Advancing Translational Sciences (NCATS): Government-funded translational research entity that bridges academic discoveries and clinical development; thematically related translational mission but funded by public sources rather than a single private capital pool.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ancora Innovation